Haemocompatibility of nanosized drug delivery systems: Has it been adequately considered?

Journal of Biomedical Nanotechnology

Volumn 4, Issue 3, 2008, Pages 218-233

  Michanetzis, Georgios P A K ^a   Missirlis, Yannis F ^a   Antimisiaris, Sophia G ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Biocompatibility; Drug; Drug delivery; Haemocompatibility; Haemolysis; Hemocompatibility; Hemolysis; Nanoparticles

Indexed keywords

BLOOD; DRUG DELIVERY; NANOPARTICLES;

DRUG; HAEMOCOMPATIBILITY; HAEMOLYSIS; HEMOCOMPATIBILITY; HEMOLYSIS;

BIOCOMPATIBILITY;

AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; CARBON NANOTUBE; CHITOSAN; CONTRACEPTIVE AGENT; CURCUMIN; CYTOTOXIC AGENT; DENDRIMER; DOXORUBICIN; DRUG CARRIER; ESTRADIOL; FUSIDIC ACID; HEPARIN; LIPOSOME; MACROGOL; NANOCAPSULE; NANOCARRIER; NANOMATERIAL; NANOPARTICLE; PEPTIDE DERIVATIVE; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIDE; POLYMER; PROTEIN DERIVATIVE; QUANTUM DOT; RAPAMYCIN; RIFAMPICIN; SOLID LIPID NANOPARTICLE; UNINDEXED DRUG;

ADSORPTION; ANALYTIC METHOD; BIOCOMPATIBILITY; BIODEGRADABILITY; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD COMPATIBILITY; CARDIOTOXICITY; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONFERENCE PAPER; CYTOLOGY; CYTOTOXICITY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FORMULATION; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; FILTRATION; FOOD AND DRUG ADMINISTRATION; HEMOLYSIS; HUMAN; HYDROPHILICITY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MEDICAL INSTRUMENTATION; METHODOLOGY; MICELLE; MOLECULAR WEIGHT; NANOTECHNOLOGY; NANOTOXICOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; QUALITY CONTROL; SKIN TOXICITY; STANDARDIZATION; SURFACE PROPERTY; TERATOGENICITY; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE STRUCTURE;

EID: 58149241369     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2008.327     Document Type: Conference Paper

References (85)

1. F. Mohamed and C. F. Van Der Walle, Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J. Pharm. Sciences 97, 71 (2008).
2. S. Parveen and S. K. Sahoo, Polymeric nanoparticles for cancer therapy. J. Drug Target 16, 108 (2008).
3. J. K. Vasir and V. Labhasetwar, Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 59, 718 (2007).
4. J. Szebeni, C. R. Alving, L. Baranyi, and R. Bunger, Interactions of liposomes with complement leading to adverse reactions, Liposome Technology, edited by G. Gregoriadis, Informa Healthcare USA, New York, NY, USA (2007), Vol. III, pp. 1-19.
5. S. G. Antimisiaris, P. Kallinteri, and D. G. Fatouros, Liposomes in drug delivery, Pharmacautical Manufacruring Handbook: Production and Processes, edited by S. C. Gad, John Wiley and Sons Inc., Hoboken, NJ, USA (2008), pp. 443-533.
6. P. P. Constantinides, M. V. Chaubal, and R. Shorr, Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv. Drug Deliv. Rev. 60, 757 (2008).
7. S. Sofou, Surface-active liposomes for targeted cancer therapy. Nanomedicine 2, 711 (2007).
8. A. A. Date, M. D. Joshi, and V. B. Patravale, Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev. 59, 505 (2007).
9. H. L. Wong, R. Bendayan, A. M. Rauth, Y. Li, and X. Y. Wu, Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59, 491 (2007).
10. P. Blasi, S. Giovagnoli, A. Schoubben, M. Ricci, and C. Rossi, Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev. 59, 454 (2007).
11. B. Rihova, Biocompatibility of biomaterials: Hemocompatibiity, immunocompatibility and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers. Adv. Drug Deliv. Rev. 21, 157 (1996).
12. S. T. Stern and S. E. McNeil, Nanotechnology safety concerns revisited. Toxicol. Sciences 101, 4 (2008).
13. D. B. Warheit, T. R. Webb, V. L. Colvin, K. L. Reed, and C. M. Sayes, Pulmonary bioassay studies with nanoscale and fine-quartz particles in rats: Toxicity is not dependent upon particle size but on surface characteristics. Toxicol. Sciences 95, 270 (2007).
14. D. B. Warheit, W. J. Brock, K. P. Lee, T. R. Webb, and K. L. Reed, Comparative pulmonary toxicity inhalation and instillation studies with different TiO2 particle formulations: Impact of surface treatments on particle toxicity. Toxicol. Sciences 88, 514 (2005).
15. A. Hoshino, K. Fujioka, T. Oku, M. Suga, Y. F. Sasaki, T. Ohta, M. Yasuhara, K. Suzuki, and K. Yamamoto, Physicochemical properties and cellular toxicity of nanocrystal quantum dots depend on their surface modification. Nano Lett. 4, 2163 (2004).
16. P. R. Lockman, J. M. Koziara, R. J. Mumper, and D. Allen, Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J. Drug Target 12, 635 (2004).
17. A. M. Derfus, W. C. W. Chan, and S. N. Bhatia, Probing the cytotoxicity of semiconductor quantum dots. Nano Lett. 4, 11 (2004).
18. V. S. W. Chan, Nanomedicine: An unresolved regulatory issue. Regulatory Toxicol. Pharmacol. 46, 218 (2006).
19. J. M. Davis, How to assess the risks of nanotechnology: Learning from past experience. J. Nanosci. Nanotechnol. 7, 1 (2007).
20. G. Oberdörster, E. Oberdörster, and J. Oberdörster, Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 113, 823 (2005).
21. J. S. Tsuji, A. D. Maynard, P. C. Howard, J. T. James, C.-W. Lam, D. B. Warheit, and A. B. Santamaria, Research strategies for safety evaluation of nanomaterials, Part IV: Risk assessment of nanoparticles. Toxicol. Sci. 89, 42 (2006).
22. G. Oberdörster, A. Maynard, K. Donaldson, V. Castranova, J. Fitzpatrick, K. Ausman, J. Carter, B. Karn, W. Kreyling, D. Lai, S. Olin, N. Monteiro-Riviere, D. Warheit, and H. Yang, Principles for characterizing the potential human health effects from exposure to nanomaterials: Elements of a screening strategy. Part Fibre Toxicol. 2, 1743 (2005).
23. http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/ scenihr_o_003b.pdf;http://www.nanotec.org.uk/finalReport.htm
24. K. Morgan, Development of a preliminary framework for informing the risk analysis and risk management of nanoparticles. Risk Analysis 25, 1621 (2005).
25. D. F. Williams, A model of biocompatibility and its evaluation. J. Biomed. Eng. 11, 185 (1989).
26. N. Lewinski, V. Colvin, and R. Drezek, Cytotoxicity of nanoparticles. Small 4, 26 (2008).
27. R. Duncan and L. Izzo, Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 57, 2215 (2005).
28. D. S. Kohane, Microparticles and nanoparticles for drug delivery. Biotech. and Bioengin. 96, 203 (2007).
29. K. Rodgers, Hemocompatibility, Encyclopedia of Toxicology, edited by Ph. Wexler, Elsevier Inc. (2005), pp. 497-500.
30. Y. F. Missirlis, How to deal with the complexity of the blood-polymer interactions. Clinical Materials 11, 9 (1992).
31. B. D. Ratner, The catastrophe revisited: Blood compatibility in the 21st Century. Biomaterials 28, 5144 (2007).
32. Annual book of ASTM Standards (2001). Section 13, Medical devices and Services, West Conshohocken, PA:ASTM: ASTM F78-98 "Standard Practice for Selecting Generic Biological Test Methods for Materials and Devices;" ASTMF756-93: "Standard Practice for Assessment of Haemolytic Properties of Materials;" ASTM F1841-97: "Standard Practice for Assessment of Haemolysis in Continuous Flow Blood Pumps" ISO 10993-4:2002 Biological evaluation of medical devices: Part 4: Selection of tests for interactions with blood; ISO 1135-3: "Blood Taking Set" and ISO 3826-4: "Plastic Collapsible Containers for Human Blood and Blood components."
33. G. W. Hastings, Structural considerations and new polymers for biomedical applications. Polymer 26, 1331 (1985).
34. R. S. Langer and N. A. Peppas, Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials 2, 201 (1981).
35. J. J. Marty, R. C. Oppenheim, and P. Speiser, Nanoparticles-new colloidal drug delivery system. Pharm. Acta Helvetiae 53, 17 ( 1978).
36. L. S. Nair and C. T. Laurencin, Biodegradable polymers as biomaterials. Prog. Polym. Sci. 32, 762 (2007).
37. J. B. Hall, M. A. Dobrovolskaia. A. K. Patri, and S. E. McNeil, Characterization of nanoparticles for therapeutics. Nanomedicine 2, 789 (2007).
38. R. L. Juliano, M. J. Hsu, D. Peterson, S. L. Regen, and A. Singh, Interactions of conventional or photopolymerized liposomes with platelets in vitro. Experimental Cell Research 146, 422 (1983).
39. E. Hasegawa, K. Eshima, Y. I. Matsushita, H. Nishide, and E. Tsuchida, Interactions of functionalized polymeric liposomes having a porphinato-iron complex with some biological cells and components in vitro. Biochimica et Biophysica Acta (BBA)-Biomembranes 862, 235 ( 1986).
40. C. Chouly, L. Bordenave, R. Bareille, V. Guerin, A. Baquey, D. Pouliquen, C. H. Baquey, and P. Jallet, In vitro study of the hemocompatibility of superparamagnetic contrast agent for magnetic resonance imaging. Clinical Materials 15, 293 (1994).
41. M. Lück, K. F. Pistel, Y. X. Li, T. Blunk, R. H. Müller, and T. Kissel, Plasma protein adsorption on biodegradable microspheres consisting of poly(D,L-lactide-co-glycolide), poly(L-lactide) or ABA triblock copolymers containing poly(oxyethylene): Influence of production method and polymer composition, poly(-lactide) or ABA triblock copolymers containing poly(oxyethylene): Influence of production method and polymer composition. J. Controlled Release 55, 107 (1998).
42. C. Passirani, G. Barratt, J. P. Devissaguet, and D. Labarre, Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. Life Sciences 62, 775 (1998).
43. J. M. Schierholz and G. Pulverer, Investigation of a rifampin, fusidicacid and mupirocin releasing silicone catheter. Biomaterials 19, 2065 (1998).
44. A. Sahli, M. Cansell, J. Tapon-Bretaudière, D. Letourneur, J. Jozefonvicz, and A. M. Fischer, The stability of heparin-coated liposomes in plasma and their effect on its coagulation, Colloids and Surfaces B: Biointerfaces 10, 205 (1998).
45. A. Yamazaki, F. M. Winnik, R. M. Cornelius, and J. L. Brash, Modification of liposomes with N-substituted polyacrylamides: Identification of proteins adsorbed from plasma. Biochimica et Biophysica Acta (BBA)-Biomembranes 1421, 103 (1999).
46. K. Ishihara, Bioinspired phospholipid polymer biomaterials for making high performance artificial organs. Science and Technology of Advanced Materials 1, 131 (2000).
47. K. Ishihara, R. Tsujino, M. Hamada, N. Toyoda, and Y. Iwasaki, Stabilized liposomes with phospholipid polymers and their interactions with blood cells. Colloids and Surfaces B: Biointerfaces 25, 325 (2002).
48. T. Konno, K. Kurita, Y. Iwasaki, N. Nakabayashi, and K. Ishihara, Preparation of nanoparticles composed with bioinspired 2-methacryloyloxyethyl phosphorylcholine polymer. Biomaterials 22, 1883 (2001).
49. K. T. Nguyen, S. H. Su, A. Sheng, D. Wawro, N. D. Schwade, C. F. Brouse, P. E. Greilich, L. Tang, and R. C. Eberhart, In vitro hemocompatibility studies of drug-loaded poly-(L-lactic acid) fibers. Biomaterials 24, 5191 (2003).
50. C. Olbrich, A. Gessner, W. Schödder, O. Kayser, and R. H. Müller, Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene - cytotoxicity testing and mouse serum adsorption. J. Controlled Release 96, 425 (2004).
51. P. J. Photos, L. Bacakova, B. Discher, F. S. Bates, and D. E. Discher, Polymer vesicles in vivo: Correlations with PEG molecular weight, J. Controlled Release 90, 323 (2003).
52. B. Qiang, A. Segev, I. Beliard, N. Nili, B. H. Strauss, and M. V. Sefton, Poly(methylidene malonate 2. 1. 2) nanoparticles: A biocompatible polymer that enhances peri-adventitial adenoviral gene delivery. J. Controlled Release 98, 447 (2004).
53. X. Shuai, H. Ai, N. Nasongkla, S. Kim, and J. Gao, Micellar carriers based on block copolymers of poly(σ-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J. Controlled Release 98, 415 (2004).
54. J. P. Xu, J. Ji, W. D. Chen, D. Z. Fan, Y. F. Sun, and J. C. Shen, Phospholipid based polymer as drug release coating for cardiovascular device. Eur. Polym. J. 40, 291 (2004).
55. D. W. Lee, K. Powers, and R. Baney, Physicochemical properties and blood compatibility of acylated chitosan nanoparticles. Carbohydrate Polymers 58, 371 (2004).
56. R. R. Palmer, A. L. Lewis, L. C. Kirkwood, S. F. Rose, A. W. Lloyd, T. A. Vick, and P. W. Stratford, Biological evaluation and drug delivery application of cationically modified phospholipid polymers. Biomaterials 25, 4785 (2004).
57. M. C. Chen, H. F. Liang, Y. L. Chiu, Y. Chang, H. J. Wei, and H. W. Sung, A novel drug-eluting stent spray-coated with multi-layers of collagen and sirolimus. J. Controlled Release 108, 178 (2005).
58. H. J. Wang, Z. X. Lin, X. M. Liu, S. Y. Sheng, and J. Y. Wang, Heparin-loaded zein microsphere film and hemocompatibility. J. Controlled Release 105, 120 (2005).
59. C. J. Pan, J. J. Tang, Y. J. Weng, J. Wang, and N. Huang, Preparation, characterization and anticoagulation of curcumin-eluting controlled biodegradable coating stents. J. Controlled Release 116, 42 ( 2006).
60. G. Tepe, J. Schmehl, H. P. Wendel, S. Schaffner, S. Heller, M. Gianotti, C. D. Claussen, and S. H. Duda, Reduced thrombogenicity of nitinol stents - In vitro evaluation of different surface modifications and coatings. Biomaterials 27, 643 (2006).
61. M. D. Dhanaraju, R. RajKannan, D. Selvaraj, R. Jayakumar, and C. Vamsadhara, Biodegradation and biocompatibility of contraceptive-steroid-loaded poly(dl-lactide-co-glycolide) injectable microspheres: In vitro and in vivo study. Contraception 74, 148 (2006).
62. Y. Geng and D. E. Discher, Visualization of degradable worm micelle breakdown in relation to drug release. Polymer 47, 2519 (2006).
63. K. R. Kamath, J. J. Barry, and K. M. Miller, The Taxus™ drug-eluting stent: A new paradigm in controlled drug delivery. Adv. Drug Deliv. Rev. 58, 412 (2006).
64. R. K. Kainthan, M. Gnanamani, M. Ganguli, T. Ghosh, D. E. Brooks, S. Maiti, and J. N. Kizhakkedathu, Blood compatibility of novel water soluble hyperbranched polyglycerol-based multivalent cationic polymers and their interaction with DNA. Biomaterials 27, 5377 (2006).
65. G. Koromila, G. P. A. Michanetzis, Y. F. Missirlis, and S. G. Antimisiaris, Heparin incorporating liposomes as a delivery system of heparin from PET-covered metallic stents: Effect on haemocompatibility. Biomaterials 27, 2525 (2006).
66. K. S. C. R. dos Santos, J. F. J. Coelho, P. Ferreira, I. Pinto, S. G. Lorenzetti, E. I. Ferreira, O. Z. Higa. and M. H. Gil, Synthesis and characterization of membranes obtained by graft copolymerization of 2-hydroxyethyl methacrylate and acrylic acid onto chitosan. Int. J. Pharm. 310, 37 (2006).
67. C. J. Pan, J. J. Tang, Z. Y. Shao, J. Wang, and N. Huang, Improved blood compatibility of rapamycin-eluting stent by incorporating curcumin. Colloids and Surfaces B: Biointerfaces 59, 105 (2007).
68. J. L. Italia, D. K. Bhatt, V. Bhardwaj, K. Tikoo, and M. N. V. Ravi Kumar, PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral®. J. Controlled Release 119, 197 (2007).
69. 2 nanotubes in the enhancement of blood clotting for the control of hemorrhage. Biomaterials 28, 4667 (2007).
70. Y. K. Lee, J. H. Park, H. T. Moon, D. Y. Lee, J. H. Yun, and Y. Byun, The short-term effects on restenosis and thrombosis of echinomycin-eluting stents topcoated with a hydrophobic heparin-containing polymer. Biomaterials 28, 1523 (2007).
71. R. Fernández-Pacheco, C. Marquina, J. G. Valdivia, M. Gutiérrez, M. S. Romero, R. Cornudella, A. Laborda, A. Viloria, T. Higuera, A. García, J. A. G. de Jalón, and M. R. Ibarra, Magnetic nanoparticles for local drug delivery using magnetic implants. J. Magn. Magn. Mater. 311, 318 (2007).
72. G. Mittal, D. K. Sahana, V. Bhardwaj, and M. N. V. Ravi Kumar, Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J. Controlled Release 119, 77 (2007).
73. E. Cenni, D. Granchi, S. Avnet, C. Fotia, M. Salerno, D. Micieli, M. G. Sarpietro, R. Pignatello, F. Castelli, and N. Baldini, Biocompatibility of poly(d,l-lactide-co-glycolide) nanoparticles conjugated with alendronate. Biomaterials 29, 1400 (2008).
74. H. H. Cho, D. W. Han, K. Matsumura, S. Tsutsumi, and S. H. Hyon, The behavior of vascular smooth muscle cells and platelets onto epigallocatechin gallate-releasing poly(l-lactide-co--̇caprolactone) as stent-coating materials. Biomaterials 29, 884 (2008).
75. X. Wang, X. Zhang, J. Castellot, I. Herman, M. Iafrati, and D. L. Kaplan, Controlled release from multilayer silk biomaterial coatings to modulate vascular cell responses. Biomaterials 29, 894 (2008).
76. P. Ferreira, J. F. J. Coelho, and M. H. Gil, Development of a new photocrosslinkable biodegradable bioadhesive. Int. J. Pharm. 352, 172 (2008).
77. S. Azarmi, W. H. Roa, and R. Löbenberg, Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev. 60, 863 (2008).
78. A. Rehor, H. Schmoekel, N. Tirelli, and J. A. Hubbell, Functionalization of polysulfide nanoparticles and their performance as circulating carriers. Biomaterials 29, 1958 (2008).
79. L. Y. Huang and M. C. Yang, Surface immobilization of chondroitin 6-sulfate/heparin multilayer on stainless steel for developing drug-eluting coronary stents. Colloids and Surfaces B: Biointerfaces 61, 43 (2008).
80. J. L. Brash and D. L. Lyman, Adsorption of plasma proteins in solution to uncharged, hydrophobic polymer surfaces. J. Biomed. Mater Res. 3, 175 (1969).
81. S. M. Moghimi and J. Szebeni, Stealth liposomes and long circulating nanoparticles: Critical issuues in pharmacokinetics, opsonization and protein-binding proteins. Progress in Lipid Res. 42, 463 (2003).
82. N. Kukreja, Y. Onuma, J. Daemen, and P. W. Serruys, The future of drug-eluting stents. Pharmacol Res. 57, 171 (2008).
83. Nanotechnology, A report of the US Food and Drug Administration Nanotechnology Task Force, July 25 (2007).
84. http://ec.europa.eu/health/ph_risk/documents/synth_report.pdf (Synthesis report) http://ec.europa.eu/health/ph_risk/documents/ stakeholder_comments.zip. (Stakeholder comments).
85. S. K. Sahoo and V. Labhasetwar, Drug Discovery Today 8, 1112 ( 2003).